Pharma stocks slide after new tweet from Trump on drug prices
Share of Eli Lilly and Co. and numerous other drug industry stocks fell Tuesday morning after the president sent a tweet promising to lower medicine costs for American people.
Eli Lilly and Co.
Articles
Why former Mayor Peterson is stepping down from drugmaker Eli Lilly
Getting elected mayor requires fine-tuned political instincts. Sometimes, those instincts say it’s time to leave a high-level job at the biggest company in town.
Drug companies willing to spend big in pursuit of Alzheimer’s cure
Alzheimer’s disease is rewriting the rules of drug discovery, with companies like Eli Lilly and others abandoning caution to keep pursuing an elusive hypothesis because the potential payoff is so great.
Former Mayor Peterson leaving Lilly after seven years
Eli Lilly and Co. said Bart Peterson, who served two terms as Indianapolis mayor, was stepping down as senior vice president "to pursue personal business interests" and expand his community volunteer commitments.
As pricing criticism mounts, Lilly, other drugmakers roll out pay for performance
In Lilly’s partnership with Harvard Pilgrim Health Care, the not-for-profit insurer gets additional rebates if fewer patients using Lilly's diabetes treatment Trulicity meet blood sugar goals than expected.
Merck stops Alzheimer’s study after ‘no chance’ of benefit
Merck & Co. on Tuesday announced that it will end a study of its once-promising Alzheimer’s disease drug in patients with mild-to-moderate forms of the condition, just three months after Eli Lilly and Co. announced its own setback in a field that’s been littered with failures.
Eli Lilly aims to cut 200 R&D jobs
The Indianapolis-based drugmaker has offered many of its research and development employees a compensation package if they leave the company.
Lilly CEO encouraged by Trump meeting, concerned about Obamacare
Eli Lilly and Co. CEO Dave Ricks said he was encouraged by President Donald Trump’s understanding of the complexities of drug development, yet he’s concerned about risks the industry may face in a fresh overhaul of the U.S. health-care system.
Trump spoils pharma chiefs with no more bad news on drug pricing
For drugmakers, including Indianapolis-based Eli Lilly and Co., a meeting Tuesday with President Donald Trump was a dose of happy pills.
UPDATE: Trump tells drugmakers, including Lilly, their prices are ‘astronomical’
President Trump took Big Pharma to task on pricing but also promised to ease regulations and find ways to speed medicines to market, which triggered a surge in the sector’s share prices.
Eli Lilly earnings rise sharply but narrowly miss analysts’ expectations
The Indianapolis-based drugmaker got a revenue boost from a host of new medications but also saw sales fall sharply for some older products.
Lilly shares rise after Alimta cancer drug patent upheld on appeal
Teva Pharmaceuticals Industries Ltd.’s proposed generic version infringes a patent on the multi-billion-dollar patent, the U.S. Court of Appeals for the Federal Circuit ruled.
Lilly exec Azar departs as new CEO makes organizational changes
Alex Azar, president of Lilly USA LLC since 2012, is leaving the company just as his unit is about to lose a huge swath of sales personnel. The drugmaker announced a series of changes Thursday under new CEO David Ricks.
2016 TOP STORIES: Lilly Alzheimer’s drug fails in high-stakes trial
t was the most closely watched experimental drug from Eli Lilly and Co. in years, a potential game-changer for treating the ravages of Alzheimer’s disease.
Lilly shares jump after it offers better-than-expected forecast
Eli Lilly and Co. shares rose sharply Thursday morning after the company presented a better-than-expected 2017 forecast nearly a month after it had announced the failure of a key Alzheimer’s treatment in testing.
Lilly trims profit guidance but says growth strategy on track
The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
Lilly to sell insulin at 40 percent discount to cash-paying patients
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
Pharma stocks slide after Trump’s vow to control drug costs
President-elect Donald Trump promised to drive down the cost of medicines, defying investors who saw a boon in his election last month and injecting himself again into a contentious economic debate.
Lilly threatens Sanofi’s dominance in insulin with knockoff drug
In a few days, a new type of knockoff medicine will upend a $10 billion diabetes-drug market and exacerbate a brutal price war between some of its biggest players.
After rough November, some good news for Lilly
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.